Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells

International Journal of Molecular Medicine

Volumn 39, Issue 2, 2017, Pages 297-306

  Luo, Yunpeng ^a   Che, Wen ^a   Zhao, Mingyan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

High mobility group box 1; Lipopolysaccharide; Nuclear factor B; Toll like receptor 2; Ulinastatin

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYELOPEROXIDASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; ULINASTATIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CYTOKINE; GLYCOPROTEIN; LIPOPOLYSACCHARIDE; PEROXIDASE; PROTEIN BINDING; TRYPSIN INHIBITOR;

A-549 CELL LINE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RESPIRATORY TRACT PARAMETERS; TRANSCRIPTION INITIATION; WESTERN BLOTTING; WET TO DRY WEIGHT RATIO; ACUTE LUNG INJURY; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; DRUG EFFECTS; GENETICS; LUNG; LUNG ALVEOLUS EPITHELIUM CELL; METABOLISM; PATHOLOGY;

ACUTE LUNG INJURY; ALVEOLAR EPITHELIAL CELLS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HMGB1 PROTEIN; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MALE; NF-KAPPA B; PEROXIDASE; PROTEIN BINDING; RATS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRYPSIN INHIBITORS;

EID: 85012048367     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2828     Document Type: Article

References (34)

1. Su CF, Kao SJ and Chen HI: Acute respiratory distress syndrome and lung injury: Pathogenetic mechanism and therapeutic implication. World J Crit Care Med 1: 50-60, 2012.
2. Castellheim A, Brekke OL, Espevik T, Harboe M and Mollnes TE: Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69: 479-491, 2009.
3. Jing H, Yao J, Liu X, Fan H, Zhang F, Li Z, Tian X and Zhou Y: Fish-oil emulsion (omega-3 polyunsaturated fatty acids) attenuates acute lung injury induced by intestinal ischemia-reperfusion through Adenosine 5'-monophosphate-activated protein kinase-sirtuin1 pathway. J Surg Res 187: 252-261, 2014.
4. Song Z, Zhao X, Gao Y, Liu M, Hou M, Jin H and Cui Y: Recombinant human brain natriuretic peptide ameliorates trauma-induced acute lung injury via inhibiting JAK/STAT signaling pathway in rats. J Trauma Acute Care Surg 78: 980-987, 2015.
5. Lin WC, Chen CW, Huang YW, Chao L, Chao J, Lin YS and Lin CF: Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep 5: 12463, 2015.
6. Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ and Wang H: Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: An updated review. Expert Rev Clin Immunol 10: 713-727, 2014.
7. Agalave NM and Svensson CI: Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain. Mol Med 20: 569-578, 2015.
8. Wang H, Ward MF and Sama AE: Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets 18: 257-268, 2014.
9. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
10. Lutz W and Stetkiewicz J: High mobility group box 1 protein as a late-acting mediator of acute lung inflammation. Int J Occup Med Environ Health 17: 245-254, 2004.
11. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296-301, 2004.
12. Ye C, Choi JG, Abraham S, Wu H, Diaz D, Terreros D, Shankar P and Manjunath N: Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci USA 109: 21052-21057, 2012.
13. van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11: 91-99, 2008.
14. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924, 2006.
15. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ and Billiar TR: Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 19: 88-98, 2013.
16. Hirata Y, Kurobe H, Higashida M, Fukuda D, Shimabukuro M, Tanaka K, Higashikuni Y, Kitagawa T and Sata M: HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. Atherosclerosis 231: 227-233, 2013.
17. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX and Liu MH: Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-a and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 64: 543-547, 2012.
18. Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, Fan S, Zhou H and Zheng J: Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 17: 799-807, 2013.
19. Gao C, Li R and Wang S: Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg 72: 169-176, 2012.
20. Li W, Qiu X, Jiang H, Zhi Y, Fu J and Liu J: Ulinastatin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of AMPK/NF-?B pathway. Int Immunopharmacol 29: 560-567, 2015.
21. Huang N, Wang F, Wang Y, Hou J, Li J and Deng X: Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res 182: 296-302, 2013.
22. Shen W, Gan J, Xu S, Jiang G and Wu H: Penehyclidine hydrochloride attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Pharmacol Res 60: 296-302, 2009.
23. Wang F, Meng Y, Zhang Y, Zhao G, Zheng X, Xiao Q and Yu Y: Ketamine reduces lipopolysaccharide-induced high-mobility group box-1 through heme oxygenase-1 and nuclear factor erythroid 2-related factor 2/p38 mitogen-activated protein kinase. J Surg Res 194: 599-613, 2015.
24. Sung YH, Shin MS, Ko IG, Kim SE, Kim CJ, Ahn HJ, Yoon HS and Lee BJ: Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor-?B in BV2 mouse microglial cells. Int J Mol Med 31: 1030-1036, 2013.
25. Feng G, Sun B and Li TZ: Daidzein attenuates lipopolysaccharide-induced acute lung injury via toll-like receptor 4/NF-kappaB pathway. Int Immunopharmacol 26: 392-400, 2015.
26. Tianzhu Z and Shumin W: Esculin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of TLR/NF-?B pathways. Inflammation 38: 1529-1536, 2015.
27. Kawasaki T and Kawai T: Toll-like receptor signaling pathways. Front Immunol 5: 461, 2014.
28. Chang Y, Huang X, Liu Z, Han G, Huang L, Xiong YC and Wang Z: Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res 181: 308-314, 2013.
29. Liu Z, Zhang J, Huang X, Huang L, Li S and Wang Z: Magnesium sulfate inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated RAW264.7 macrophages in vitro. J Surg Res 179: E189-e195, 2013.
30. Liu Z, Chang Y, Zhang J, Huang X, Jiang J, Li S and Wang Z: Magnesium deficiency promotes secretion of high-mobility group box 1 protein from lipopolysaccharide-activated macrophages in vitro. J Surg Res 180: 310-316, 2013.
31. Yang Q, Liu X, Yao Z, Mao S, Wei Q and Chang Y: Penehyclidine hydrochloride inhibits the release of high-mobility group box 1 in lipopolysaccharide-activated RAW264.7 cells and cecal ligation and puncture-induced septic mice. J Surg Res 186: 310-317, 2014.
32. Yamauchi Y, Izumi Y, Inoue M, Sugiura H, Goto T, Anraku M, Ohtsuka T, Kohno M, Soejima K and Nomori H: Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS One 6: E29053, 2011.
33. Inoue K and Takano H: Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 19: 513-520, 2010.
34. Maciejewski R, Burdan F, Burski K, Madej B, Ziemiakowicz R, Dabrowski A and Wallner G: Selected biochemical parameters and ultrastructural picture of pancreas due to Ulinastatin treatment of experimental acute pancreatitis. Exp Toxicol Pathol 56: 305-311, 2005.